Omnicell Inc
Research Omnicell Inc (OMCL) on Bullrun: valuation model: 66.2% overvalued, market cap USD 1.86B, P/E 92.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOMCL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyUSD
- Valuation signal66.2% overvalued
- Market capUSD 1.86B
- P/E92.8
- Financial periodFY2025
- RevenueUSD 1.18B
- Revenue growth6.5%
- Net incomeUSD 2.05M
- Free cash flowUSD 86.89M
- Gross margin42.5%
Valuation Snapshot
Bullrun's latest valuation model marks Omnicell Inc as 66.2% overvalued; latest market cap is USD 1.86B; P/E is 92.8.
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing;
Frequently asked questions
Is Omnicell Inc overvalued or undervalued?
Bullrun's valuation model currently marks Omnicell Inc as 66.2% overvalued.
What is Omnicell Inc's market cap?
Omnicell Inc's market capitalization is USD 1.86B.
What is Omnicell Inc's P/E ratio?
Omnicell Inc's price-to-earnings (P/E) ratio is 92.8.
What does Omnicell Inc do?
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system;